ArticleRheumatology (Oxford, England)2026
Prevalence of dysautonomia in chronic musculoskeletal pain: a cross-sectional study.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesThere is substantial evidence that the autonomic nervous system plays a crucial role in pain modulation and chronicity, but the actual prevalence of dysautonomia in musculoskeletal conditions remains unknown. This study investigated the prevalence of dysautonomia in patients with chronic musculoskeletal pain (CMP) compared with healthy controls, quantified the dysautonomia burden in inflammatory and non-inflammatory musculoskeletal conditions, and evaluated the associations between pain severity, psychological factors and dysautonomia severity.
methodsThis cross-sectional study recruited patients with CMP between October 2024 and July 2025 along with healthy participants with similar age-sex distribution. Inclusion criteria were a clinician-confirmed musculoskeletal condition and pain duration >12 weeks. Assessments included the Composite Autonomic Symptom Score-31, the Brief Pain Inventory and the Hospital Anxiety and Depression Scale. A COMPASS-31 score of 17 or higher was considered indicative of dysautonomia.
resultsOf 896 patients screened, 342 participated, along with 57 healthy controls. Dysautonomia was significantly more prevalent in CMP patients (74%) compared with controls (11%) (adjusted RR = 7.4, 95% CI 1.8-13.1, P = 0.010). Dysautonomia rates were similarly high in inflammatory (76%) and non-inflammatory (72%) conditions. Risk of dysautonomia increased with pain severity (RR 1.27 per point on BPI, 95% CI 1.08-1.45, P < 0.001), depression (RR 1.12 per HADS depression score, 95% CI 1.06-1.19, P < 0.001) and anxiety (RR 1.15 per HADS anxiety score, 95% CI 1.08-1.22, P < 0.001), adjusting for age and gender.
conclusionDysautonomia is highly prevalent among patients with CMP irrespective of inflammatory status and is associated with pain severity, depression and anxiety. CMP patients should be assessed for dysautonomia as a potential contributor to symptom burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.